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Abstract
Exposure to influenza viruses is necessary, but not sufficient, for healthy human hosts to develop symptomatic illness. The
host response is an important determinant of disease progression. In order to delineate host molecular responses that
differentiate symptomatic and asymptomatic Influenza A infection, we inoculated 17 healthy adults with live influenza
(H3N2/Wisconsin) and examined changes in host peripheral blood gene expression at 16 timepoints over 132 hours. Here
we present distinct transcriptional dynamics of host responses unique to asymptomatic and symptomatic infections. We
show that symptomatic hosts invoke, simultaneously, multiple pattern recognition receptors-mediated antiviral and
inflammatory responses that may relate to virus-induced oxidative stress. In contrast, asymptomatic subjects tightly
regulate these responses and exhibit elevated expression of genes that function in antioxidant responses and cell-mediated
responses. We reveal an ab initio molecular signature that strongly correlates to symptomatic clinical disease and
biomarkers whose expression patterns best discriminate early from late phases of infection. Our results establish a temporal
pattern of host molecular responses that differentiates symptomatic from asymptomatic infections and reveals an
asymptomatic host-unique non-passive response signature, suggesting novel putative molecular targets for both
prognostic assessment and ameliorative therapeutic intervention in seasonal and pandemic influenza.
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Introduction
Influenza viruses are highly infectious and can cause acute
respiratory illness in human hosts. Infected hosts present a variety
of clinical symptoms including fever, runny nose, sore throat,
myalgias, and malaise with potentially more serious complications
such as viral pneumonia [1]. Many hosts also withstand com-
parable level of viral insult with little or no overt symptoms,
exhibiting a higher degree of tolerance [2,3]. Clearly, these
asymptomatic infected hosts are able to control and eradicate viral
threats more effectively than those who become symptomatic.
Given the dynamic nature of viral infection, it is now recognized
that interactions between hosts and viruses play a crucial role in
determining the presence and absence of symptoms [4]. This leads
to an interesting question _ what are the principal factors
associated with such divergent disease outcome?
In recent years, seminal studies on the sensing of pathogens by
pattern-recognition receptors (PRRs) and their related signaling
cascades have advanced our understanding of innate immunity
[5–10]. Many elegant experimental analyses have further eluci-
dated the mechanistic activation and modulation of host response
to invading pathogens [11–16]. By design, however, host re-
sponses in these experimental conditions are often characterized
for individual cells via cell culture; or they represent a snapshot of
the immune response pertaining to a limited number of time
points. The components of the host immune system are diverse
and they interact in a complicated manner. Owing to both
technical and ethical difficulties, it has not been practical to
experimentally determine the full course of immune responses
leading to severe symptoms in otherwise healthy human hosts.
Thus the time sequence and orchestration of host response events
remain to be fully understood.
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The peripheral blood contains key elements of the immune
system and the circulating immune cells recruited by the host in
response to viral infection and virus-induced tissue damage
provides a global view of the host immune response. Thus, we
hypothesized that it can be used to monitor the temporal dynamics
of host-virus interactions. Analyzing whole-genome gene expres-
sion profiles from healthy human subjects challenged with
influenza H3N2/Wisconsin, we studied the full temporal spectrum
of virus-mediated disease dynamics. Going beyond the peak
symptom time analysis reported in Zaas et al. [17], this report
offers an hour-by-hour detailed view of host immune response as a
continuum, spanning the time from exposure to peak symptom
manifestation. Utilizing biological and mathematical models, we
highlight key immune response events representing potential
factors that determine the pathogenicity of influenza viral infec-
tion. We further present a statistical risk-stratification model for
estimating current disease state with potential forward risk assess-
ment capability. These results are concordant with findings
reported by Zaas et al. that was limited to peak symptom time
analysis.
Results
Outline of overall analysis strategy
A cohort of 17 healthy human volunteers (Table S1) received
intranasal inoculation of influenza H3N2/Wisconsin and 9 of
these subjects developed mild to severe symptoms based on
standardized symptom scoring [18]. Gene expression profiles were
measured on whole peripheral blood drawn from all subjects at an
interval of ,8 hours post inoculation (hpi) through 108 hpi. A
total of 267 gene expression profiles were obtained for all subjects
at 16 time points including baseline (224 hpi). As outlined in
Figure S16, our analysis of the data consists of two parallel
components: 1) clinically uninformed (unsupervised) factor analysis
using Bayesian Linear Unmixing (BLU) [19]; 2) clinically informed
(supervised) pathway analysis using EDGE [20] and self organizing
maps (SOM) [21] that leverages clinical and temporal covariates
for increased statistical power. The former establishes the existence
of an ab initio molecular signature that strongly correlates to
symptomatic clinical disease. The later further reveals important
host factors that delineate time courses of designated symptomatic
(Sx) and asymptomatic (Asx) subjects.
A genomic signature discriminates between early and
late stages of disease
Symptomatic infection exhibits a distinct time evolving mole-
cular signature. This signature is sufficiently strong that a clinically
uninformed factor analysis method is able to pick it up without
using any clinical phenotype information such as disease outcome,
subject or time labels. For this analysis we used the BLU factor
analysis method described in the Methods section. Figure 1A
shows a heatmap of the linear combination (BLU factor score) of
genes in this signature, where for visualization we have arranged
the samples in a matrix whose rows and columns are organized
according to clinical phenotype of the subject and sample time.
The image of the BLU factor score shown in Figure 1A bears
striking resemblance to the standardized clinical symptom obser-
vation matrix in Figure 1B.
The BLU factor score signature is sufficiently strong that
application of a threshold to the post-inoculation part of the
heatmap in Figure 1A perfectly divides the subjects into asympto-
matic subjects (Class 2) and symptomatic subjects before onset
(Class3) and after onset (Class 4) of acute infection. The selection of
the threshold was based on the pre-inoculation samples (Class 1) and
is described in the Methods section. Then, using logistic regression
[22] as an association measure between class label and gene
expression, we extracted sets of genes that are most associated with
differences between pairs of classes (Table S4). When the expression
profiles of these genes are plotted as heatmaps (Figure 1C) the
contrasts in gene expression are striking. For example, the type-I
interferon antiviral response related genes IFI44L, IFI27, GBP1,
RTP4, and OAS1 are among the most associated with differenti-
ating acute infection (class 4) from the other 3 classes. As another
example, note the contrast between complement component 3a
receptor (C3AR1) between Classes 2 and 3, exhibiting a marked
change after inoculation in symptomatic subjects. These genes are
well known for their critical function in host immunity [6,23,24].
This demonstrates both the strength of the genomic signature of
acute infection and the utility of BLU factor analysis for ab initio
discovery of this signature.
Identification of eight distinct virus-mediated gene
expression dynamics
When we add clinical and temporal information about the
samples to the analysis we can identify clusters of genes whose
temporal expression patterns differentiate immune response of
clinically asymptomatic from clinically symptomatic subjects.
Using EDGE with false discovery rate (FDR) significance level
(q-value),0.01, we selected 5,076 genes whose temporal expres-
sion profiles differed significantly between Asx and Sx phenotypes.
Heatmaps of these 5,076 EDGE genes are shown in Figure S18.
Next, these 5,076 gene expression profiles were grouped into
clusters based on using SOM applied jointly to the Sx and Asx
phenotypes. A total of eight clusters were identified and their
associated centroids are shown in Figure 2A and 2C as polar and
linear plots of expression over time. Heatmaps of gene expression
Author Summary
The transcriptional responses of human hosts towards
influenza viral pathogens are important for understanding
virus-mediated immunopathology. Despite great advances
gained through studies using model organisms, the
complete temporal host transcriptional responses in a
natural human system are poorly understood. In a human
challenge study using live influenza (H3N2/Wisconsin)
viruses, we conducted a clinically uninformed (unsuper-
vised) factor analysis on gene expression profiles and
established an ab initio molecular signature that strongly
correlates to symptomatic clinical disease. This is followed
by the identification of 42 biomarkers whose expression
patterns best differentiate early from late phases of
infection. In parallel, a clinically informed (supervised)
analysis revealed over-stimulation of multiple viral sensing
pathways in symptomatic hosts and linked their temporal
trajectory with development of diverse clinical signs and
symptoms. The resultant inflammatory cytokine profiles
were shown to contribute to the pathogenesis because
their significant increase preceded disease manifestation by
36 hours. In subclinical asymptomatic hosts, we discovered
strong transcriptional regulation of genes involved in
inflammasome activation, genes encoding virus interacting
proteins, and evidence of active anti-oxidant and cell-
mediated innate immune response. Taken together, our
findings offer insights into influenza virus-induced patho-
genesis and provide a valuable tool for disease monitoring
and management in natural environments.
Temporal Host Molecular Responses to Influenza A
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Figure 1. The BLU genetic signature correlates strongly with disease severity and yields early- and late-stage risk stratification
model. (A) The scores of the top ranked factor detected by the unsupervised BLU factor analysis method. Each microarray sample is represented by
one square cell of the image and ordered by phenotype and subject (row-wise) and increasing time (column-wise). Color palette is coded according
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are shown for the top 5 genes in each SOM cluster (Figure 2B).
These eight clusters decompose temporal host response into eight
distinct classes of differential expression dynamics, revealing
divergent trends in asymptomatic and symptomatic responses
over time. The contrasts in expression patterns between pheno-
types are all statistically significant (q-value,0.01) (Figure 2C).
Most clusters show significant monotonic increase or decrease in
expression over time in Asx or Sx phenotypes (Table S3). For Sx
subjects we define three stages of infection: early (0–12 hpi),
middle (12–45 hpi), and late (.45 hpi).
Collectively, clusters 2, 3, 4, and 6 contain more than 78% of all
significant genes and highlight the sharp contrasts in expression
dynamics between phenotypes. Although the discussion below
focuses on these four clusters, pathway enrichment analysis indi-
cates that genes from all eight clusters are directly related to the
activation and modulation of host immune and inflammatory
responses (Table 1). Clusters 3 and 4 contain genes that are asso-
ciated with equally strong Sx response but responded discordantly.
Cluster 3 is denoted as (Anc,S
up
mid ) where superscripts nc and up
stands for no change and upregulation, respectively. The subscript
mid (middle stage) indicates the onset time of the change. Cluster 3
is characterized by strong activation, in Sx phenotype, of genes
responsible for antiviral and inflammatory responses. Cluster 4,
(Anc,Sdwmid ), contains genes that are continuously down-regulated in
the Sx phenotype in contrast to nearly no change in the Asx
phenotype. On the other hand, genes in clusters 2 and 6 are
associated with strong but discordant responses in both Asx and Sx
individuals, indicating an active physiological response in Asx
hosts. Cluster 2, (Adwearly,S
up
mid ), includes genes exhibiting sustained
decrease unique to the Asx phenotype from early time onward. In
Sx, the expression of cluster 2 genes increases to peak level at the
middle of challenge (45–69 hpi), followed by a rescinding trend.
Cluster 6, (A
up
early,S
dw
mid ), is populated by genes whose expression
steadily increases in the asymptomatic phenotype over all time. In
contrast, for the symptomatic subjects these genes exhibit a
transient but significant decrease beginning at 29 hpi and return to
baseline after 60 hpi.
Host transcription signatures are highly correlated with
disease dynamics
The eight clusters represent molecular signatures of unique and
contrasting temporal dynamics. We evaluated whether these
signatures are related to symptom development by correlating
the expression of these signatures against standardized clinical
symptom scores [17,18]. Both positive and negative correlations
were observed (Figure 3C). In particular, cluster 3 (Anc,S
up
mid )
showed the strongest positive correlation with symptom scores
(r=0.77) followed by cluster 2 (r=0.58). The temporal expression
pattern of cluster 3 genes closely resembled the disease progression
trajectory of each individual Sx subject. It is noteworthy that luster
3 is most significantly enriched with 70% of the BLU factor genes
(p,0.05; Fisher’s exact test). This is in strong concordance with the
BLU gene expression signature being highly correlated with
temporal disease progression (Figure 3A and 3B). Furthermore,
90% of ‘‘acute respiratory viral’’ signature genes are found in
cluster 3 (Table S5) [17]. In comparison, the lack of symptoms in
Asx subjects was consistent with their nearly-constant low-level
expression of this same cluster of genes (Figure 3B). Interestingly, the
two largest clusters, cluster 4 (Anc,Sdwmid ) and cluster 6 (A
up
early,S
dw
mid ),
were the most negatively correlated with the development of
symptoms, (r=20.54) and (r=20.41) respectively (Figure 3C).
These demonstrate the close association between the host tran-
scriptional signatures and the overt clinical disease development.
Cluster 6 contains significant proportion of genes
encoding influenza virus interacting proteins
A recent study identified 66 and 87 human proteins that
physically interact with H3N2/Udorn and H1N1/A/PR/8/34
(PR8) viruses, respectively [25]. We examined the distribution of
genes corresponding to these proteins among the eight clusters
identified in our analysis. Several interesting findings result from
the comparison. A total of 27 (45%) and 40 (46%), respectively, of
genes overlap with the set of differentially expressed genes found in
our study (Figure 3D). The majority of these genes (67%) are
found in cluster 4 and 6. Except for clusters 2 and 3, the H3N2/
Udorn and H1N1/PR8 genes are distributed in a similar
proportion across the eight SOM clusters. Such similarity shows
functional conservation between the two viral strains. Secondly,
cluster 6 alone contains 44% of the 27 overlapping genes (H3N2/
Udorn). This is significantly disproportional to the size of cluster 6
(p-value,0.05; Fisher exact test). Several of the overlapping genes
such as PRKRA, MAPK9, and NRF1 have been shown to play
important roles in host immune or antioxidant function. Thirdly,
cluster 2 and 3 showed a significantly lower proportion of
overlapping genes (p-value,0.05; Fisher’s exact test). These results
suggest that genes in these two clusters are more likely to be
indirectly regulated by the viruses such as those involved in
inflammatory responses. Taken together, the results independently
validate the functional relevance of the molecular signatures
identified in our challenge study and suggest that many cluster 6
genes might be directly regulated by viruses.
The host antiviral program is activated 36 hours before
peak symptom time
An examination of the highest ranked genes in cluster 3
(Anc,S
up
mid ) reveals strong activation of host antiviral defense
program (Table 1). These genes include several PRR genes such
as Toll-like receptor 7 (TLR7), the RNA helicases (RIG-I), and
interferon induced with helicase C domain 1 (IFIH1) – genes
encodes proteins that are key to innate immune responses by
acting as viral RNA sensors [12,26–28]. These are among the
most statistically significant (q-value,0.0001; EDGE), exhibiting
dramatic increase of expression starting at 45 hpi in Sx hosts
(Figure 4B, Figure S8). Previous studies have demonstrated that
the downstream signaling triggered by these PRRs converge at
TANK-binding kinase 1 (TBK1), resulting in direct phosphory-
lation of interferon regulatory factor 7 (IRF7) [29]. Both TBK1
and IRF7 (Figure S1) have similar expression dynamics and are
found in cluster 3. In total, cluster 3 contains 11 genes from the
to the enrichment factor score determined by BLU. The higher the score, the warmer (red) color representation of the sample. The numbers (1 to 4)
are the disease state (class) designation determined by BLU (3 and 4) and inoculation time (1 and 2). The boundary between 3 and 4 occurs at
samples that are labeled (To) denoting the critical transition point (onset time) of Sx subject transcriptome profiles. The grey color (absolute 0
loading) corresponds to samples that were not assayed. (B) Clinical symptom chart of corresponding subjects (rows) and times (columns) that are
ordered in the same manner as A. (C) Heatmap of groups of genes that are most highly associated with differences between pairs of classes
according to a logistic regression model. For purposes of visualization, the heatmaps show gene expression profiles that are averaged over Asx (left)
and Sx (right) phenotypes and are smoothed over time using the same cubic spline fitting method as used for heatmaps shown in Figure 2B.
doi:10.1371/journal.pgen.1002234.g001
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Figure 2. Self-organizing map clusters show distinct transcriptional dynamics in Influenza H3N2/Wisconsin virus challenge study.
(A) Polar plots of the 8 SOM clusters and their associated gene expression patterns. Each segment plot represents the prototype of a cluster.
Individual time points are scaled and ordered in sequence and phenotype around the circle. Specifically, the temporal expression of Asx resides on
the top portion of the circle while Sx expression occupies the bottom half. Each phenotype’s expression values are placed in time sequence, with
Temporal Host Molecular Responses to Influenza A
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TLR signaling pathway, including MyD88, TRAF6, and STAT1.
As a group, they showed an aggregated effect that is significantly
associated with the symptomatic disease. This association reaches
statistical significance (p,0.05; Globaltest) at 53 hpi with an
increasing trend appearing as early as 36 hours before peak
symptom time. By 93 hpi, the association attains its maximum
level of significance with all 11 member genes significantly upre-
gulated (Figure 4A, Figure S1).
The activation of PRRs by viral ligands triggers downstream
signaling cascades that include both antiviral and inflammatory
responses. In line with this, cluster 3 contains many such
downstream effector genes that were fully activated with similar
dynamics. Several interferon-stimulated antiviral genes, such as
MX1, OAS1, RSAD2, PKR, exhibit Sx-specific significant tem-
poral activation beginning at 36–45 hpi (Figure 4C, Figure S3,
Figure S9). This increase persists many hours beyond symptom
peak time, suggesting non-rescinding efforts in viral resolution by
the host. It is noteworthy that none of the type-I interferon genes
themselves is differentially expressed between the Sx and Asx
phenotypes. Similarly, cluster 3 also contains many elements of the
inflammatory branch of TLR signaling, e.g., the interferon regu-
latory factor 5 (IRF5). As a master regulator of the inflammatory
arm of TLR7 signaling [9], IRF5 directly activates proinflamma-
tory cytokine tumor necrosis factor alpha (TNF), which has been
directly implicated in flu-like symptoms in many types of diseases
with excessive inflammation. These and other mediators of
inflammatory response such as IL15 and IL10 genes share similar
Asx-specific increasing pattern (Figure 4D, Figure S7). Of interest,
the sialic acid binding Ig-like lectin 1 (SIGLEC1 or Sialoadhesin)
was strongly activated in Sx hosts at mid-to-late stage of infection
(Figure 4D). As a macrophage-specific adhesion molecule,
SIGLEC1 has recently been related to pro-inflammatory function
of macrophages in HIV infections [30]. These results show that
the expression kinetics of cluster 3 genes constitutes a transcrip-
tional signature of host antiviral program. This signature fully
presents itself 36 hours before the peak symptom time and it is
indicative of disease severity. Moreover, its activation intensity
maintained high level through 108 hpi.
An active asymptomatic state is characterized by down-
regulated expression of the NLRP3 inflammasome,
CASP5, and the IL1B pathway
Members of cytoplasmic Nod/NACHT-LRR (NLR) family
have recently been linked to pathogen pattern recognition. Ori-
ginally identified in bacterial infections, this family of molecules is
important to the function of innate immunity [31–33]. A recent
study showed that nucleotide-binding oligomerization domain 2
(NOD2) recognizes ssRNA of both Influenza and respiratory
syncytial viruses [34]. Furthermore, activated NODs were linked
to the activation of receptor-interacting serine-threonine kinase
2 (RIPK2) and subsequently nuclear factor kappa-B (NFkB)
activation whereas activated NLPRs result in forming so-
called inflammasome complexes. This process involves caspase-
1 (CASP1) and caspase-5 (CASP5) and ultimately the release of
time increasing in the counterclock-wise direction, inside its own half circle. The degrees of angle are equally divided among segments within the
circular plot. The different lengths of radii of the segments represent the deviation of a time point from the average expression level of the complete
time course. (B) Heatmaps of EDGE-estimated temporal profiles of the top 5 genes from each SOM cluster (EDGE averages over Asx (left) and Sx
subjects (right) and smoothes over time using a fitted cubic spline). Genes in each cluster are ordered in decreasing order of EDGE significance level
(See Figure S18 for heatmaps of all significant genes found by EDGE). (C) Centroids of each SOM cluster show individual cluster average expression
profile and corresponding +two standard deviations. The statistical significance of phenotype-specific trend of expression monotonicity can be
found in Table S3. hpi: hours post inoculation.
doi:10.1371/journal.pgen.1002234.g002
Table 1. Canonical pathways and representative genes enriched in individual SOM clusters.
SOM Cluster # of Genes Pathway Representative Genes
1 450 immune cell trafficking; antigen presentation CD74, HLA-DMA, HLA-DPA1, HLA-DPB1, CCR5, CCL4, TBX21, IL10RA,
CD244, ICAM2
2 759 inflmmation; chemotaxis of macrophage,
neutrophils, and dendritic cells; antigen
presentation, JAK-STAT signaling
SOCS1, SOCS3, NOD2, NLRP3, CASP5, IL1B, STAT3, ADM,C5, CCL2/7/8/11,
CCR1, CCR4, CD14, CD59, CD163, CD209, CEACAM3, CXCL9, CXCL10,
CXCL11, FAS, HLA-B, ICAM1, IL17RB, IL18R1, IL18RAP, LILRA2, LTBR, MX2,
TGFB1, TLR1, TLR2, TLR4, TLR5, TLR8, TREM2, TRIM21, SERPINA1, CASP4,
IFITM2
3 739 inflammatory response; dendritic cell and
neutrophil activation; IFN-signaling
TLR7, MYD88, IRF7, IRF5, IRF9, TNF, JAK2, PSMB8, STAT1, DDX58, IFIH1,
IL18, IL10, MX1, RSAD2, OAS1, SIGLEC1, NOD1, CASP1, PKR, TRIM22,
LILRB1, ISG20, IFNAR1, IFI44, CD86, CD40, CD63, C1QA, IL10RB, TNFRSF14,
TNFSF10, TNFSF12, BTK, RNASE2; C3AR1, CYBB, FASLG, APOL3, ANXA2,
IFI35, IFIT1, IFIT3, IFITM1, IFITM3
4 1175 oxidative stress; ca+ induced T cell
apoptosis; iCOS signaling
CCL5, RPS6KA5, ACTG1, CUL3, PRKC GENES, C-JUN, PIK3 family, MAP2K4,
CD3E, CD247, CD40LG, CAMK4M, IL2RB, ITK, ITPR1, ITPR3, LAT, NFATC1,
NFATC3, ICOS, FYN
5 228 antigen presentation; innate immune
response
CD97, THBD, DDX17, IL1R2, ORM1, TREM1, AOC3, FOXO3, IL1R1, IL1RAP,
AQP9, CA4, CAMK1D
6 1326 protein synthesis; oxidative stress; RNA
trafficking; JAK-STAT signaling
SOCS2, SOCS5, SOD1, SOK1, RPL3, EIF3 FAMILY GENES, CCR7, RPS9,
RPS14, RPL22, C1QBP, DDX21, DDX50, ICOS
7 228 natural killer cell signaling; cell apoptosis SIGLEC7, ASC, SHC1, MAPK7, KIR2DL1, KIR2DS4, KIR3DL1, SERPINF1, RAC1,
CD4, CX3CR1, HLA-G, TNFRSF1B, ITGB2, CTSD
8 171 cell morphology; cell signaling EIF2AK1, LY96, BCL2L1, KRAS, PIM1, TGM2, RGS1, PKN2
doi:10.1371/journal.pgen.1002234.t001
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pro-inflammatory and pro-oxidant cytokine interleukin 1-beta
(IL1B) [35,36].
The NLR-related genes are among the most highly differentially
expressed genes discovered in our study. These genes appear
in two clusters, cluster 2 (Adwearly,S
up
mid ) and cluster 3 (A
nc,S
up
mid ),
exhibiting markedly different temporal patterns (Figure 2). Resid-
ing in cluster 3, NOD1, RIPK2 and CASP1 showed no significant
change in Asx subjects (q-value.0.01; EDGE) but highly increased
among Sx individuals (q-value,0.0001; EDGE) (Figure 5A, Figure
S2). On the other hand, NOD2, NLPR3, and CASP5 are found in
cluster 2. Their expression decreased in Asx but increased
evidently in Sx (Figure 5B, Figure S2). In addition, the expression
level of IL1B (cluster 2) was evidently suppressed in the Asx
phenotype while activated in the Sx phenotype (Figure 5C). Given
the importance of NOD2 and NLPR3 to the processing of IL1B,
the Asx specific lower expression of IL1B may be contributed
directly to the similar downregulation patterns of NOD2 and
NLRP3. This hypothesis is supported by a new study in which
Nod2-deficient mice showed decreased levels of TNF and IL1B in
PBMC [34].
Of relevance to the phenotypically different expression dynamics
of NLR-mediated inflammasome activation, an opposite trend is
observed in two cluster 6 (A
up
early,S
dw
mid ) genes that are related to
cellular response to oxidative stress. The superoxide dismutase
(SOD1) and serine/threonine kinase 25 (STK25 or SOK1) are
markedly activated in Asx subjects, contrasting to the transient
suppression pattern (45–60 hpi) in Sx hosts (Figure 5D, Figure S10).
As SOD1 and STK25 both have been linked to anti-oxidant/stress
response and reduced concentration of ROS [37–39], their sustained
up-regulation in Asx hosts highlights a host response signature
unique to the Asx phenotype. This signature may relate to the
concomitant suppression of NLRP3 and IL1B in Asx individuals.
Collectively, our data reveal a phenotypically divergent expression of
NLR family genes and inflammasome signaling, which may be
related to the host anti-oxidant response.
Distinct temporal kinetics of JAK-STAT pathway and
SOCS family genes reveals a potential anti-inflammatory
and viral control mechanism in Asx hosts
A hallmark of host recognition of viral RNA is the activation of
Janus kinase-signal transducer and activator of transcription (JAK-
STAT) pathway, which is crucial for the antiviral function of
interferons. However, such activation is tightly controlled to limit
the possibility of over-stimulating inflammatory cytokine-receptor
signals. As an integral component of the JAK-STAT pathway, the
family of suppressor of cytokine signaling (SOCS) proteins have
recently been reported to negatively regulate the response of
Figure 3. Strong correlation of molecular signature with disease severity. (A) Clinical symptom scores of symptomatic subjects with
individuals represented by curves in different colors. (B) Cluster 3 gene expression of symptomatic subjects (top) and Asx subjects (bottom). (C) The
correlation coefficients (total variance explained) between standardized symptom scores and SOM clusters. (D) Cluster-wise distribution of genes
encoding proteins that are known to interact with H1N1/PR8 and H3N2/Udorn viruses. The proportion of genes encoding virus-human interaction
proteins in a cluster is compared to the relative size of that cluster for determining significance of distributional differences (Fisher’s exact test;
*,0.05, **,0.005).
doi:10.1371/journal.pgen.1002234.g003
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immune cells to cytokine signals [40]. Using pathway analysis, we
detected significantly distinct JAK-STAT signaling dynamics (p-
value,0.05; Globaltest), involving two different sets of SOCS
genes. The first set included SOCS1 and SOCS3 from cluster 2
(Adwearly,S
up
mid ) while the second group consists of SOCS2 and
SOCS5 from cluster 6 (A
up
early,S
dw
mid ). The expression of SOCS1 and
SOCS3 declines at early time points among Asx but strongly
increases among Sx (Figure 6A, Figure S11). Growing evidence
suggests that SOCS1 and SOCS3 are important inhibitory modu-
lators in limiting the inflammatory effect of interferon signaling
during viral infection [41,42]. Our data supports such a protective
role of SOCS1 and SOCS3 given their much higher levels of
expression during late infection phase (45 hpi onward).
Consistent with cluster 6 but contrasting with the cluster 2
expression pattern (Figure 2), SOCS2 and SOCS5 exhibits
expression dynamics that clearly differ from that of SOCS1 and
SOCS3. Starting from the early infection stage (&12 hpi), SOCS2
and SOCS5 show marked increasing trend in Asx and this trend
persists throughout the entire infection period (Figure 6B, Figure
S11). In contrast, their expression diminishes in Sx, especially
between 45 hpi and 69 hpi. A recent study showed that the anti-
inflammatory actions of aspirin-induced lipoxins depend upon the
function of SOCS2 [43]. Highly expressed in lymphoid organs,
SOCS5 was hypothesized to be important for the generation of
Th1 responses by repressing IL-4-induced signals that promote
Th2 differentiation [44]. In addition, we observed a significant
positive association of interleukin 7 (IL7) and STAT4 (Figure 6B).
Of these, STAT4 transduces IL12 and IFN-A cytokine signals in T
cells and monocytes [45] whereas IL7 is critical for proper T cell
response and expansion during viral infection [46–48]. Taken
together, the distinct expression patterns of SOCS family genes
and related JAK-STAT signaling suggest possible early involve-
ment of Th1-type adaptive immune response in Asx hosts with no
sign of excessive inflammation.
Ribosomal protein synthesis genes are upregulated in
Asx subjects as compared to Sx subjects
In addition to expression changes in magnitude, genes in
clusters 2 (Adwearly,S
up
mid ) and 6 (A
up
early,S
dw
mid ) also exhibit directional
contrast between two phenotypes. As the largest cluster with a total
of 1,326 member genes, cluster 6 contains genes with expression
profiles similar to those of SOCS2 and SOCS5. Among them, we
found an unusual saturation of genes related to ribosomal protein
synthesis. Out of 47 significant genes in this pathway, 35 (76%) of
them are located in cluster 6 (p-value,0.0001; x2test). Together,
these 35 genes correlated positively with Asx phenotype (p-
value,0.05; Globaltest) and their expression increased over the
course of the study (Figure 6C). Such association emerges at 45–
53 hpi and peaks at 60 hpi, at which point every one of the 35
genes becomes highly expressed. Individually, all genes showed
increased expression trend (Figure S4). This trend can be seen at
as early as 5 hpi and as late as 108 hpi. In contrast, Sx subjects
showed sustained down-regulation of the same set of genes, with
lowest expression level at 60 hpi. This decreasing trend continues
until ,84 hpi, which coincides with the peak symptom time
observed in symptomatic subjects (Figure 3). In addition, these 35
genes include 53% of 13 genes whose expression are characteristic
of peripheral blood lymphocytes (Figure 6D) [49], suggesting
prominent presence of lymphocytes in the blood of Asx subjects
during infection. This is further supported by the increased
number of whole blood leukocytes in Asx subjects (Figure S17).
Given the markedly contrasting trends observed between Asx and
Sx phenotypes, we conclude that Asx hosts responded differently
to the viral insult by inducing leukocyte response with enhanced
cellular protein biosynthesis.
Discussion
Pathogenic influenza A viral infection is a complex and dynamic
process that involves various components of the host immune
system at different stages of infection in response to virus-induced
physiological changes. Dissecting the temporal host response to
invading viruses and subsequent symptomatic disease process are
crucial for studying disease pathogenesis and related host factors.
Equally important is to understand the complexity of the host
response in individuals who are exposed but effectively contain the
infection and avoid symptomatic disease. This study presents key
transcriptional differences between Asx and Sx host responses, and
highlights an active state (on a gene transcription level) of viral
control in both Sx and Asx hosts.
Viral sensing, inflammation, and symptomatic disease
We showed that the viral sensing and inflammation in Sx hosts
clearly correlate to clinical symptom development over time. As
mounting evidence has established the role of various PRRs in
sensing viral components of influenza viruses, our results confirm
the concurrent activation of all known classes of PRRs and their
signaling cascades by influenza viruses in human challenge
models. In contrast, Asx hosts showed not only an absence of
such activation, but also negative regulation of related inflamma-
tory signals, especially in the case of NLRP3 and NOD2. This
corresponds to their lack of clinical apparent symptoms.
It has long been postulated that multiple PRRs represent a
functional redundancy of host defense and that there exists
signaling crosstalk among them, stimulating similar cytokine
profiles that are both pro-inflammatory and pro-oxidant [36].
Here we found simultaneous and continued activation of all
known PRRs in Sx hosts with particular emphasis on NLR family
genes. Of important relevance, two recent studies showed that
H1N1 1918 pandemic virus induced upregulation of inflamma-
some components in a macaque model while avian H5N1 virus
Vietnam/1203/04 caused increasing expression of NLR family
genes in mice [50,51]. In both cases, the early and sustained
upregulation of inflammasome component genes was directly
associated with lethal or detrimental host responses. Abnormal
expression of NOD2 has been implicated in inflammatory bowel
disease [52,53]. Conversely, it was shown in a study on chronic
arthritis that Nod2 gene-deficiency resulted in reduced joint
inflammation and increased protection against early cartilage
damage in mice [54]. Our results provide new evidence for a
much broader role played by NLR-family genes during influenza
viral infection that is likely to be shared by multiple viral strains
Figure 4. Similar expression dynamics of TLR7-pathway effector genes in cluster 3. (A) Significance of association (p-value) between Toll-
like receptor (TLR) pathway and overall symptom severity. Significant positive association between TLR-pathway genes and symptom severity is
shown at 53 hpi (top left). The temporal expression of representative significant genes on TLR-pathway that are related to pattern recognition (TLR7
and RIG-I) (B); antiviral: myxovirus resistant 1 (MX1) and 29,59-oligoadenylate synthetase 1 (OAS1) (C); and pro-inflammatory: TNF and SIGLEC-1 (D).
The expression intensities are plotted on a log base 2 scale and all genes are differentially expressed between Asx and Sx (q-valueƒ0.0001; EDGE).
doi:10.1371/journal.pgen.1002234.g004
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Figure 5. Divergent expression patterns of Nod/NACHT-LRR (NLRs) family of genes from cluster 2 and cluster 3 with contrasting
expression of anti-oxidant/stress genes SOD1 and STK25 (or SOK1). (A) SOM cluster 3 genes nucleotide-binding oligomerization domain
containing 1 (NOD1) and caspase 1 (CASP1) display strong temporal upregulation in symptomatic subjects. (B) SOM cluster 2 genes NOD2 and
NLRP3 exhibit downregulation in Asx hosts and upregulation in symptomatic subjects. (C) SOM cluster 2 gene interleukin 1 beta (IL1B) shows
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and influenced by specific cellular context. Their contrasting
expression dynamics in Sx versus Asx points to potential benefit in
controlling inflammation by regulating NLRP3-mediated inflam-
masome activation or other inflammatory responses [55].
Link between anti-oxidant response and Asx infection
The inflammasome and pro-inflammatory cytokines have been
linked to increased level of oxidative stress during viral infection
[56–58]. A recent report showed in mouse model that Nlrp3
inflammasome activation depends on reactive oxygen species
(ROS) and inhibition of ROS induction abolished IL1B
production during influenza infection [59]. It is intriguing that
our data shows a temporal Asx-specific upregulation versus Sx-
specific suppression of SOD1 and SOK1. This coincides with the
observed negative correlation between these genes and NLRP3.
Since SOD1 and SOK1 are capable of reducing ROS and of
suppressing oxidative stress [37], their increased expression in Asx
hosts may play a role in negatively regulating NLRP3 expression
and inflammasome signaling. In support of this hypothesis is a
study on the efficacy of antioxidant therapy found that pyran
polymer-conjugated SOD1 protected mice against potentially
lethal influenza virus infections [38]. Together, our results provide
evidence for a protective role of antioxidants SOD1 and SOK1.
Their increased mRNA expression may constitute an effective
antiviral mechanism by which aberrant immune responses are
avoided in Asx hosts.
The nature of Asx phenotype
It is estimated that Asx infections account for 30–50% of
seasonal flu cases [2], which is consistent with the attack rate in our
study. Since both Asx and Sx subjects were challenged under the
same protocol and displayed inoculation dosage-independent viral
shedding, this raises a critical question concerning the nature of
the observed Asx phenotype. We have strong evidence that the
observed Asx molecular signatures are a consequence of rapid
innate response rather than being due to failed inoculation. Firstly,
50% of Asx subjects had evident viral shedding. This is on par with
that of ‘‘subclinical’’ or ‘‘secondary’’ infections reported in the
literature. In addition, serum neutralizing antibody (nAb) titre
were nearly identical in Asx and Sx subjects on day 0 and day
7 with pre-inoculation nAb independent of disease severity.
Critically, the nAb titre increased over time in both Asx and Sx
individuals (Figure S12). This indicates a boosting effect of
immunity, and suggests that even if viral replication was inhibited,
enough viruses were detected by the Asx host immune system to
cause expansion of Ab producing cells. Secondly, there was no
apparent dosage effect – subjects who received relatively lower
amount of inoculation do not necessarily become more ill than
individuals who received higher dose of virus. We found no
statistically significant dependence between disease outcome and
inoculation dosage (Figure S13A). Furthermore, the amount of
viral shedding from the site of infection did not appear to differ
among groups who received varying inoculation doses (Figure
S13B). Thirdly, Asx subjects presented dramatic transcriptional
responses towards inoculation. When their expression profiles
were studied alone, more than 3,000 genes showed significant
post-infection expression changes. These changes do not correlate
with the amount of virus detected. Two subjects (#3 and #17)
who never yielded detectable virus (,1.25 TCID50/mL) in their
nasal wash appeared to have the most significant temporal
suppression of gene NLRP3 (Table S2; Figure S14; Figure S15).
Additionally, the responses of two seroconverted Asx subjects (#2
and #3), according to haemagglutination inhibition (HAI) assay,
are not different from those of other Asx individuals (Table S2;
Figure S14; Figure S15).
With all presented evidence supporting the activation of a
robust Asx immune response, our findings point to an important
host factor that may lead to such Asx subclinical infections.
Shutting down protein synthesis helps control infection by
inducing apoptosis of infected cells [60–62]. Consistent with this,
we observed marked downregulation of protein biosynthesis and
apoptosis related genes in Sx hosts at mid-to-late stages (Figures
S4, S5, S6). A similar lowering expression of ribosomal proteins
has been reported in measles-infected dendritic cells [63]. What is
surprising is the sustained upregulation of as many as 35 ribosomal
proteins in only Asx subjects (Figure 6C, Figure S4). The increased
ribosomal gene expression has been associated with peripheral
blood lymphocytes [49] and our data also showed significant
increase of white blood cells in Asx subjects (Figure S17). Lacking
strong PRRs activation, and hence an absence of adaptive
immune response, these Asx hosts appeared to be capable of
mounting a more potent cell-mediated innate immune response
than the symptomatic subjects.
Uncontrolled factors
As our study mainly focuses on gene expression in whole
peripheral blood, it is possible that the changes observed in gene
expression levels are at least partially due to changes in cell
population. However, this is unlikely for two reasons. First, the
maximum observed change in cell populations for both Asx and
Sx hosts was no more than 80% from baseline (Figure S17).
Second, the distribution of leukocyte subpopulations is not
correlated with phenotype at baseline or throughout the time
course of the study (Table S6). Thus, the dramatic changes in gene
expression described here cannot be attributed greatly to cell
population changes. Another uncontrolled factor is that certain
subjects may have come into the study with related preconditions.
While we cannot completely dismiss the possibility of previous
exposure to other respiratory viruses, all subjects were healthy and
tested negative for H3N2 influenza antibody at pre-inoculation
time. None of the volunteers had been vaccinated for any
influenza virus in the previous 3 years. Finally, while we did not
observe subject demographics such as age, gender, or ethnicity to
be influential of final disease outcome (Table S1b), we cannot rule
out the possibility of small sample bias. We have been careful to
provide statistical safeguards against model overfitting by reporting
significance measures (p-values and q-values with qualifying
confidence intervals) that are associated with our findings.
Concluding remarks
To our knowledge, this multi-institutional collaborative study
presents the first systematic analysis of the full temporal spectrum
of pathogen-elicited host responses during influenza viral infection.
This work represents by far the most extensive in vivo human
challenge study on influenza viruses. Combined with key clinical
parameters, our results offer an opportunity to look beyond
individual signaling events and into their collective effects on
symptomatic disease pathogenicity. The detailed timing of various
symptomatic-specific upregulation versus Asx-specific downregulation over time. (D) SOM cluster 6 genes superoxide dismutase (SOD1) shows
upregulation versus downregulation in Asx and Sx hosts, respectively. The expression values are plotted on a log base 2 scale and all genes are
significantly differentially expressed between Asx and Sx (q-valueƒ0.0001; EDGE).
doi:10.1371/journal.pgen.1002234.g005
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Figure 6. Asymptomatic hosts showed unique temporal expression kinetics of cluster 6 genes related to JAK-STAT signaling
transduction and protein biosynthesis. (A,B) Distinct expression pattern of gene members in JAK-STAT pathway and their association with
symptom severity. (A) Significant positive association between genes and disease severity is shown for 60 hpi (left); temporal gene expression pattern
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immune response events in vivo will advance our understanding of
their biological and clinical relevance to influenza virus-mediated
disease progression.
Materials and Methods
Human influenza viral challenges
We performed a healthy volunteer dose-ranging intranasal
challenge with influenza A A/Wisconsin/67/2005 (H3N2) at
Retroscreen Virology, LTD (Brentwood, UK). We enrolled 17
pre-screened volunteers aged 18 to 45 years of age who provided
informed consent. All volunteers were without recent influenza-
like illness in the preceding 45 days, tested influenza A H3N2
antibody negative by HAI at pre-inoculation screening and had
not been vaccinated with a seasonal influenza vaccine within the
preceding 3 years. On day of inoculation, a dose of 106 TCID50
Influenza A manufactured and processed under current good
manufacturing practices (cGMP) by Bayer Life Sciences (Vienna,
Austria) was inoculated intranasally per standard protocol at a
varying dose (1:10, 1:100, 1:1000, 1:10000) with four to five
subjects receiving each dose. Subjects were not released from
quarantine until after the 216th hour. Blood and nasal lavage
collection continued throughout the duration of the quarantine.
All subjects received oral oseltamivir (Roche Pharmaceuticals)
75 mg by mouth twice daily prophylaxis at day 6 following
inoculation. All patients were tested negative by rapid antigen
detection (BinaxNow Rapid Influenza Antigen; Inverness Medical
Innovations, Inc) at time of discharge. All exposures were ap-
proved by the relevant institutional review boards and conducted
according to the Declaration of Helsinki.
Case definitions
Symptoms were recorded twice daily using standardized
symptom scoring [2]. The modified Jackson Score requires
subjects to rank symptoms of upper respiratory infection (stuffy
nose, scratchy throat, headache, cough, etc) on a scale of 0–3 of
‘‘no symptoms’’, ‘‘just noticeable’’, ‘‘bothersome but can still do
activities’’ and ‘‘bothersome and cannot do daily activities’’. For all
cohorts, modified Jackson scores were tabulated to determine if
subjects became symptomatic from the respiratory viral challenge.
A modified Jackson score of .=6 over the first five days period
was the primary indicator of successful viral infection [18,64] and
subjects with this score were denoted as ‘‘Symptomatic’’ (Sx). Viral
titers from daily nasopharyngeal washes were used as corrobora-
tive evidence of successful infection using quantitative PCR (Table
S2) [18,64,65]. Subjects were classified as ‘‘Asymptomatic’’ if the
Jackson score was less than 6 over the first five days of observation
and viral shedding was not documented after the first 24 hours
subsequent to inoculation. Successful inoculation in Asx hosts was
further validated by analysis of multimodal data including serum
neutralizing antibody and haemagglutination inhibition titers. For
additional evidence see discussion in Text S1. Standardized
symptom scores were tabulated at the end of each study to
determine attack rate and time of maximal symptoms (time ‘‘T’’).
The clinical disease is mild (only a single fever was observed).
Immune activation assays (such as antibody response) over the full
time course of the challenge study were not available for our
analysis.
Biological sample collections
During the challenge study, subjects had samples taken 24 hours
prior to inoculation with virus (baseline), immediately prior to
inoculation (pre-challenge) and at set intervals following challenge:
peripheral blood for serum, peripheral blood for RNA PAXgeneTM,
nasal wash for viral culture/PCR, urine, and exhaled breath
condensate. Peripheral blood was taken at baseline, then at 8 hour
intervals for the initial 120 hours and then 24 hours for the
remaining 2 days of the study. For all challenge cohorts,
nasopharyngeal washes, urine and exhaled breath condensates
were taken at baseline and every 24 hours. Samples were aliquoted
and frozen at 280uC immediately.
RNA purification and microarray analysis
RNA was extracted at Expression Analysis (Durham, NC) from
whole blood using the PAXgeneTM 96 Blood RNA Kit
(PreAnalytiX, Valencia, CA) employing the manufacturer’s
recommended protocol. While whole blood RNA is initially
extracted, a secondary procedure (B-globin reduction) was then
employed to remove the contribution of red blood cell (RBC)
RNA to the total RNA. A set of four peptide nucleic acid (PNA)
oligomers whose sequences are complementary to the 39 portions
of the alpha and beta hemoglobin RNA transcripts were added to
reduce globin RNA transcription due to RBC. The inhibition of
globin cDNA synthesis dramatically reduces the relative amount of
anti-sense, biotin-labeled cRNA corresponding to the hemoglobin
transcripts. Hybridization and microarray data collection was
performed using the Human Genome U133A 2.0 Array
(Affymetrix, Santa Clara, CA) and expression profiles were pre-
processed using robust multi-array (RMA) method [66] (Text S1).
Both raw and normalized gene expression data are available at
GEO (GSE30550).
Statistical analysis
Temporal gene expression was analyzed using EDGE [20] on
RMA normalized intensities. A total of 5,076 genes were identified
as most significantly differentially expression genes (q-value,0.01)
between Asx and Sx. Co-clustering of the significant genes found
by EDGE was performed using Self-Organizing Map [21] (Text
S1). We estimated the correlation between disease symptom scores
and temporal expression values of clusters using a standard linear
mixed model [67,68]. Specifically, for each individual symptom
measured, we regressed the scores onto the expression value vector
of each SOM cluster, separately, with a random-effects term
accounting for within-subject temporal correlation. Biological
pathway enrichment analysis was performed using Ingenuity
Pathway Analysis (IPA). We implemented the non-parametric
Jonckheere-Terpstra (JT) method [69] to test monotonicity of the
expression patterns of individual gene clusters. Briefly, the JT test
was applied independently to each cluster and configured to test
the null hypothesis that there exists no monotonic trend in the
temporal change of gene expression. This test was performed
separately for each one of two phenotypes separately. The resulted
of suppressor of cytokine signaling 1 (SOCS1) shows upregulation in symptomatic hosts. (B) Significant negative association between genes and
disease severity is shown for 60 hpi (left); temporal gene expression pattern of SOCS2 shows upregulation in Asx hosts versus downregulation in Sx
hosts. (C) Significance of negative association (p-value) between ribosomal protein synthesis (RPS)-related genes and overall disease severity; Pie
chart (top left) shows a high degree of enrichment of significant RPS genes in SOM cluster 6, which is characterized by a trend of upregulation (in Asx
hosts) versus downregulation (in symptomatic hosts) over time. (D) Proportion overlap between cluster 6 ribosomal protein synthesis genes and
lymphocyte signature ribosomal proteins genes [49].
doi:10.1371/journal.pgen.1002234.g006
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p-values were adjusted for multiple comparisons with Benjamini-
Hochberg method [70].
To identify canonical gene pathways in each SOM cluster that
are highly associated with disease phenotypes, we applied
Globaltest [71] using the pathway definition in MsigDB database
(v2.5) [72] that include both pathway components and targets. We
assessed the correlation between clinically determined symptom
scores and the temporal gene expression of SOM clusters using
standard linear mixed model regression. The correlation (R value)
was estimated using a signed coefficient of determination [67,68].
The BLU factor analysis was used to detect disease signature
shown in Figure 1A. Unlike our implementation of EDGE, SOM
and Globaltest, BLU is an unsupervised method requiring no prior
class information. Like other unsupervised Bayesian factor analysis
methods, BLU finds a decomposition of the data matrix Y, here a
p by n matrix of abundances of the p mRNA transcripts for each
of n gene expression profiles, into a matrix product MA where
each column of M is a factor and each column of A is a set of
factor loadings corresponding to individual factors in M for a
given chip:
Y~MAzN
In essence, BLU estimates two matrix valued latent variables M
and A, whose product best approximates the most important
information contained in the observation Y while minimizing the
residual model fitting error (denoted as N in the formula above)
with latent variable order selection according to an hierarchical
Bayesian model. However, unlike other factor analysis, BLU
decomposes the data into relative proportions such that the
columns of M and the columns of A are non-negative and the
columns of A sum to one. Intuitively, a BLU-discovered factor can
be viewed as a gene expression profile, whose amplitudes represent
the relative contribution of each gene present in that factor, and
the factor loadings are the proportions of these factors that are
present in each chip. Such positivity constraints aid in interpre-
tation and are natural in gene microarray analysis as the
expression intensity measurements of genes are always non-
negative.
BLU was run on all genes on the expression array and extracted
a total of three major BLU factors. The factor scores of the
samples were subsequently divided into two groups: samples taken
before inoculation (pre-inoculation samples) and samples taken
after inoculation (post-inoculation samples). We then tested for
significant difference between the scores of the pre-inoculation and
post-inoculation samples (t-test with p-value less than 0.01). At this
significance level only one of the factors passed this test – the acute
respiratory factor shown in Figure 1A. Based on the score of this
acute respiratory factor, we quantitatively determine the four
regions by a threshold criterion using the pre-inoculation samples.
The threshold was set to be more than 4 times the maximum pre-
inoculation sample score (corresponding to a t-test p-value less than
0.05) (Text S1). In this manner, all samples were labeled with one
of four classes, namely classes 1–4 (Figure 1A).The class
designation of a sample indicates distinct risk levels of four
intrinsic disease states – uninfected (class 1), infected with low-risk
for symptom development (class 2), infected with high-risk for
symptom development (class 3), and infected with overt symptoms
(class 4).
The genes exhibiting largest contrast between each pair of
classes were extracted from all genes on the expression array using
a LogitBoost classifier [73] as a contrast function. Note that our
objective is not to obtain a classifier between regions but rather to
use LogitBoost to identify groups of genes most associated with
differences between a pair of classes. As it uses boosting algorithm
to perform variable selection, our implementation of LogitBoost
yields a set of genes in addition to a classifier function. To do this,
we generated 200 bootstrap samples from each class [74]. We
randomly selected 2/3 of each bootstrap sample to construct the
boosting ensemble and the other 1/3 of data was used to evaluate
the variability of the association between the largest contrast genes
and each class pair. We defined the largest contrast genes as the set
of genes that were selected by LogitBoost algorithm for each class
pair more than 100 (50%) of the 200 bootstrap samples. The
average expression of these genes are shown in Figure 1C.
Supporting Information
Figure S1 Temporal expression of Toll-like receptor 7 pathway
member genes. Accompanying Figure 2c, temporal expression are
shown for TLR7-pathways genes (n = 11) including STAT1, IRF7,
MyD88, TLR7, TNF, CD40, IRF5, CD86, TRAF6, TBK1, and
IFNAR1. The expression intensities are averaged over subjects in
Asx and Sx phenotypes and plotted on a log base 2 scale.
(PDF)
Figure S2 Temporal expression of NLR family genes. 1) cluster
7 gene PYD and CARD domain containing (PYCARD or ASC);
2) cluster 3 gene receptor-interacting serine-threonine kinase 2
(RIPK2); 3) cluster 2 gene caspase 5 (CASP5). The expression
intensities are plotted on a log base 2 scale.
(PDF)
Figure S3 Increased temporal expression of antiviral RNA-
dependent eIF-2 alpha protein kinase (EIF2AK2 or PKR) in
cluster 3. The expression intensities are plotted on a log base 2
scale.
(PDF)
Figure S4 Phenotypically contrasting expression dynamics
ribosomal protein synthesis-related genes (n = 35) in cluster 6.
The expression intensities are averaged over subjects in Asx and
Sx phenotypes and normalized to have zero mean and unit
standard deviation.
(PDF)
Figure S5 Symptomatic-specific temporal downregulation of
cluster 4 genes (n = 9) that regulate programmed cell death
(apoptosis). A) Significance (p-value) of association between
phenotypes and the whole group of genes at all time points and
at time 45 hpi (top left panel). B) Average temporal expression
intensities are computed on subjects in Asx and Sx phenotypes and
normalized to have zero mean and unit standard deviation.
(PDF)
Figure S6 Symptomatic-specific temporal downregulation of
cluster 4 genes (n = 13) that are related to mitogen-activated
protein (MAP) kinase cascades. A) Significance (p-value) of
association between phenotypes and the whole group of genes at
all time points and at time 45 hpi (top left panel). B) Average
temporal expression intensities were computed on subjects in Asx
and Sx and normalized to have zero mean and unit standard
deviation.
(PDF)
Figure S7 Increased temporal expression of inflammatory
response regulators (cluster 3), interleukin 15 and interleukin 10.
The expression intensities are plotted on a log base 2 scale.
(PDF)
Figure S8 Temporal gene expression of cluster 3 gene
cytoplasmic double-strand viral RNA sensor IFIH1 (interferon
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induced with helicase C domain 1). The expression intensities are
plotted on a log base 2 scale.
(PDF)
Figure S9 Temporal expression of interferon inducible anti-viral
genes from cluster 3. The expression intensities are plotted on a log
base 2 scale.
(PDF)
Figure S10 Temporal gene expression of cluster 6 gene serine/
threonin kinase 25 (STK25 or SOK1). The expression intensities
are plotted on a log base 2 scale.
(PDF)
Figure S11 Temporal expression of genes from the family of
suppressor of cytokine signaling (SOCS), including cluster 2 gene
SOCS3 and cluster 6 gene SOCS5. The expression intensities are
plotted on a log base 2 scale.
(PDF)
Figure S12 Neutralizing antibody (nAb) measure prior to
inoculation shows no significant phenotypic difference and is not
correlated with disease outcome. A, B) nAb of all subjects at Day 0
(A) and day 7 (B). No difference were observed between Asx and
Sx on both days (non-parametric rank test). C) No evident
correlation between nAb on Day 0 and maximum Jackson
standardized score. A linear regression fit of score on nAb readings
is shown in dark black line. Correlation test was performed using
Spearman test. D) nAb increased in both Asx and Sx subjects from
day 0 to day 28. w No sample available on day 28.
(PDF)
Figure S13 The infection outcome and viral load are indepen-
dent of the dosage of viral inoculation. (A) There is no significant
correlation between disease outcome and inoculation dosage
(p-value = 0.2299; Fisher’s exact test). Each bar represents a
randomized group of four to five subjects receiving a varying dose
of Influenza A virus inoculation on day 0 (Supplementary
Materials). Within each group, subjects are divided into clinically
determined symptomatic (red) and asymptomatic (blue) subgroups.
(B) Viral shedding pattern (Table S2A) does not differ across
inoculation dosage groups. All nine symptomatic and four
asymptomatic subjects showed shedding $1.25. Two asymptom-
atic shedders (#14 and #16) are in lowest dosage group and the
other two (#2 and #4) are in the highest dosage group. The
amount of viral shedding are determined from nasal wash
obtained daily (Supplementary Methods). Shedding values ,1.25
are set to 1.25 in the plot.
(PDF)
Figure S14 Asymptomatic subjects demonstrated non-passive
transcriptional response program. As an example, we show a
significant temporal expression decrease of the inflammasome
related gene NLRP3 in eight individual asymptomatic subjects.
Each subpanel depicts the temporal expression of one individual
asymptomatic subject. The y-axis is the log base 2 signal intensity
of NLRP3 and the x-axis is the time from 212 hpi to 108 hpi
(hour post inoculation). A polynomial fitting of expression values
(solid line) was fitted using LOESS model and significance of
temporal trend was assessed with EDGE. Subjects #3 and #17
never showed detectable amount of virus (,1.25) in their nasal
wash (Table S2).
(PDF)
Figure S15 Serological conversion versus clinical symptom
outcome and gene expression. The RPL3 gene expression
trajectories for Asx (blue) and Sx (red) are representative of
SOM cluster 6. Legend at right gives the character encoding of
each subject along with their disease outcome (‘blue’ Asx and ‘red’
Sx) and their serologic conversion outcome (‘+’ converted and ‘2’
not converted). There is no significant relation between disease
outcome and serological conversion (p-value of 0.27 according to
likelihood ratio test of dependency between these two outcomes).
The two seroconverted asymptomatic individuals (subject #2 and
#3) are called out by orange arrows in the gene expression
trajectory plot. The RPL3 expression profiles of these two subjects
are not significantly different from those of the other asymptomatic
hosts.
(PDF)
Figure S16 Schematic outline of analysis pipeline. Unsuper-
vised: no clinical phenotype information was used. Supervised:
clinical phenotype was incorporated in analysis.
(PDF)
Figure S17 Daily white blood cell counts show mild change (less
than 80%) from baseline in Asx and Sx phenotypes.
(PDF)
Figure S18 Expression heatmap of genes that are significantly
differentially expressed between Asx and Sx. Genes are identified
using EDGE (q-value,0.01) and clustered with SOM. The
average expression are computed and normalized for each gene
to have zero mean and unit standard deviation. Within a cluster,
genes are shown in decreasing order of significance level.
(PDF)
Table S1 (A) Subject Demographic and Clinical Characteristics
of Viral Challenge Cohort. (B) Detailed subject demographics.
(PDF)
Table S2 Viral shedding and serological testing data for all
human volunteers (n = 17) challenged with Influenza H3N2
viruses. A) Measure of viral titre isolated from nasal wash over a
total of 9 days. B) Serological data on pre-screening, 224 hpi, and
+28 days.
(PDF)
Table S3 Significance of monotonic trend of gene expression in
SOM clusters. For the genes in each SOM cluster (Figure 1), we
implemented the Jonkheere-Terpstra (JT) test (Text S1) of
significance on Asx and Sx subjects, respectively, to test for
monotonic increase or decrease of gene expression over time.
Columns 2 and 3 show p-values associated with the null hypothesis
that genes in the cluster have no monotonic trend. Red colored
entries indicate clusters having highly significant monotonic
expression profiles for a particular phenotype.
(PDF)
Table S4 Discriminatory genes selected by each logistic boosting
model. Genes are listed in decreasing order based on their
discriminatory power in each model.
(PDF)
Table S5 Comparison of genes identified by Zaas et al with
significant genes in the present manuscript.
(PDF)
Table S6 The proportions of primary white blood cell (WBC)
subtypes are similar between Asx and Sx. White blood cells counts
were obtained daily through standard laboratory workout. *
Phenotype specific average percentage of cell subpopulation were
computed using Tukey’s biweight robust M-estimator. The null
hypothesis H0: the frequency distribution of WBC subtypes is
independent of disease phenotype was performed using Fisher-
exact test. H0 is rejected at significance level of 0.01.
(PDF)
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